Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial

Background Vitamin D has immunomodulatory effects both in the innate and adaptive immune systems, and there is growing scientific evidence demonstrating its relevance in inflammatory processes such as AD. Hypothesis If vitamin D3 promotes the skin immune system, then it should improve the response t...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2018-12, Vol.57 (12), p.1516-1520
Main Authors: Sánchez‐Armendáriz, Karen, García‐Gil, Ana, Romero, Cesar A., Contreras‐Ruiz, José, Karam‐Orante, Marcia, Balcazar‐Antonio, Denek, Domínguez‐Cherit, Judith
Format: Article
Language:English
Subjects:
Adaptive systems
Administration, Cutaneous
Administration, Oral
Adolescent
Adult
Atopic dermatitis
Child
Child, Preschool
Cholecalciferol - administration & dosage
Clinical trials
Dermatitis
Dermatitis, Atopic - blood
Dermatitis, Atopic - drug therapy
Dietary Supplements
Double-Blind Method
Drug Therapy, Combination
Emollients - therapeutic use
Female
Humans
Immune system
Immunomodulation
Inflammation
Male
Middle Aged
Patients
Randomization
Remission
Serum levels
Severity of Illness Index
Skin
Steroids - administration & dosage
Therapy
Vitamin D
Vitamin D - analogs & derivatives
Vitamin D - blood
Vitamin D3
Vitamins - administration & dosage
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Vitamin D has immunomodulatory effects both in the innate and adaptive immune systems, and there is growing scientific evidence demonstrating its relevance in inflammatory processes such as AD. Hypothesis If vitamin D3 promotes the skin immune system, then it should improve the response to treatment of patients with AD. Methods A randomized, double‐blind placebo‐controlled clinical trial was conducted, which included 65 patients with AD according to Hanifin–Rajka criteria and the severity scale (SCORAD). The patients were divided into two groups to receive either vitamin D3 5000 IU/day (n = 33) or placebo (n = 32), plus baseline therapy (topical steroid, soap substitute, and emollient) during 3 months. Results Fifty‐eight of the 65 enrolled subjects were included in the analysis. At the end of the intervention, the treated group achieved higher levels of 25(OH)D (P 
ISSN:0011-9059
1365-4632
DOI:10.1111/ijd.14220